AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25400004 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 120
Study 25400004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital-based rehabilitation)
Number of subjects: 120
Study 23745947 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed morphine sulfate controlled-release (CR) tablets
Number of subjects: 0
Study 23745947 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed morphine sulfate and naltrexone hydrochloride extended-release capsules (MSN)
Number of subjects: 0
Study 23745947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20888274 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA, 980-nm)
Number of subjects: 121
Study 20888274 — intervention group
Group type: COMPARATOR
Intervention: Sapheno-femoral ligation and stripping (SFL/S)
Number of subjects: 121
Study 19038705 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique with bioabsorbable screw fixation
Number of subjects: 60
Study 19038705 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique with bioabsorbable screw fixation
Number of subjects: 60
Study 16869455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 815
Study 16869455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 14618043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day MgSO(4) infusion in 100 mL 0.9 NaCl solution (25 mL/hr) for 4 days after surgery
Number of subjects: 148
Study 14618043 — intervention group
Group type: COMPARATOR
Intervention: 100 mL 0.9 NaCl solution (25 mL/hr)
Number of subjects: 148
Study 14618043 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO(4) infusion
Number of subjects: 148
Study 11051622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg bd for 7 days
Number of subjects: 0
Study 11051622 — intervention group
Group type: COMPARATOR
Intervention: Pivmecillinam 200 mg bd for 3 days
Number of subjects: 0
Study 11051622 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg bd for 3 days
Number of subjects: 0
Study 8873548 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 32
Study 8873548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 32
Study 1559143 — intervention group
Group type: EXPERIMENTAL
Intervention: Primes presented to the left visual field for high schizotypes (males)
Number of subjects: 0
Study 1559143 — intervention group
Group type: EXPERIMENTAL
Intervention: Primes presented to the right visual field for high schizotypes (males)
Number of subjects: 0
Study 1559143 — intervention group
Group type: EXPERIMENTAL
Intervention: Primes presented to both visual fields for low schizotypes (males)
Number of subjects: 0
Study 1559143 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance for females
Number of subjects: 0
Study 3160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg
Number of subjects: 11
Study 3160915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg
Number of subjects: 11
Study 3160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole, 400 mg
Number of subjects: 11
Study 30872380 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-121
Number of subjects: 0
Study 27823876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL intranasal midazolam
Number of subjects: 99
Study 27823876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL intranasal midazolam
Number of subjects: 99
Study 27823876 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL intranasal midazolam
Number of subjects: 99
Study 25946554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every 2 weeks after a loading dose)
Number of subjects: 30
Study 25946554 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (7.5-25 mg/wk)
Number of subjects: 30
Study 23394621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime administered pre-incision
Number of subjects: 180
Study 23394621 — intervention group
Group type: COMPARATOR
Intervention: Ceftizoxime administered post-clamping of the umbilical cord
Number of subjects: 180
Study 21882789 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation of clavicle fractures
Number of subjects: 28
Study 19814948 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased-dose selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 46
Study 19814948 — intervention group
Group type: COMPARATOR
Intervention: Continued SSRI plus placebo
Number of subjects: 46
Study 19814948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 46
Study 19814948 — intervention group
Group type: COMPARATOR
Intervention: Medication optimization with SSRI plus clonazepam
Number of subjects: 46
Study 16713784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual laryngoscopy
Number of subjects: 104
Study 16713784 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 104
Study 16713784 — intervention group
Group type: COMPARATOR
Intervention: BURP (Backward-Upward-Rightward Pressure)
Number of subjects: 104
Study 16713784 — intervention group
Group type: COMPARATOR
Intervention: No manipulation
Number of subjects: 104
Study 16713784 — intervention group
Group type: COMPARATOR
Intervention: BURP
Number of subjects: 104
Study 14989694 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical reconstruction of the soft palate musculature
Number of subjects: 40
Study 14989694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative gap size > 13 mm
Number of subjects: 40
Study 14989694 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of SMCP (total SMCP score of 0 to 3)
Number of subjects: 40
Study 14989694 — intervention group
Group type: EXPERIMENTAL
Intervention: Less abnormal muscle anatomy
Number of subjects: 40
Study 12123332 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-carboplatin-ifosfamide (CCI)
Number of subjects: 284
Study 12123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-carboplatin-gemcitabine (CCG)
Number of subjects: 284
Study 12123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide-gemcitabine (IG)
Number of subjects: 284
Study 10806822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 mg)
Number of subjects: 85
Study 10806822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 7973074 — intervention group
Group type: EXPERIMENTAL
Intervention: AFB (Augmented Feedback)
Number of subjects: 0
Study 7973074 — intervention group
Group type: EXPERIMENTAL
Intervention: LMFB (Learning Model Feedback)
Number of subjects: 0
Study 7973074 — intervention group
Group type: EXPERIMENTAL
Intervention: LMFB+AFB (Learning Model Feedback + Augmented Feedback)
Number of subjects: 0
Study 7973074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 3394901 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia via catheter with prilocaine combined with general anaesthesia
Number of subjects: 22
Study 3394901 — intervention group
Group type: COMPARATOR
Intervention: Modified neurolept analgesia (balanced)
Number of subjects: 22
Study 3394901 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of SaO2 using an adjusted formula
Number of subjects: 22
Study 31971296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic texture analysis on native T1-maps
Number of subjects: 188
Study 31971296 — intervention group
Group type: EXPERIMENTAL
Intervention: DTE classifier
Number of subjects: 188
Study 31971296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic analysis of native T1-images
Number of subjects: 188
Study 31621181 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Symptom Management Program (DSMP) with usual care
Number of subjects: 60
Study 31621181 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 28438471 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin treatment
Number of subjects: 567
Study 28438471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 25523883 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg, twice daily for 8 weeks)
Number of subjects: 50
Study 25523883 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 50
Study 23819225 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating acupuncture
Number of subjects: 90
Study 23819225 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Chinese herbs fumigation
Number of subjects: 90
Study 23819225 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of western medicine
Number of subjects: 90
Study 21333021 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET (web-based cognitive behavioural therapy)
Number of subjects: 140
Study 21333021 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 19772178 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile Soft-Seal Cuff (PSSC)
Number of subjects: 138
Study 19772178 — intervention group
Group type: COMPARATOR
Intervention: ProSeal LMA (PLMA)
Number of subjects: 138
Study 16442975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 10
Study 16442975 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 10
Study 16442975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15339759 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for stress urinary incontinence
Number of subjects: 20
Study 11352372 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading aloud with distorted feedback of their own voice
Number of subjects: 38
Study 11352372 — intervention group
Group type: COMPARATOR
Intervention: Reading aloud with distorted alien feedback
Number of subjects: 38
Study 9053465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose filgrastim (50 microg/m2)
Number of subjects: 38
Study 8299450 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose challenge test
Number of subjects: 22
Study 8299450 — intervention group
Group type: COMPARATOR
Intervention: 1-h postprandial study
Number of subjects: 22
Study 8299450 — intervention group
Group type: COMPARATOR
Intervention: 2-h postprandial study
Number of subjects: 22
Study 3585444 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 131
Study 3585444 — intervention group
Group type: EXPERIMENTAL
Intervention: O + CAF
Number of subjects: 131
Study 29681235 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin niosomes (MN) gel, 2.5 mg, 5 mg, and 10 mg, topically applied
Number of subjects: 14
Study 29681235 — intervention group
Group type: COMPARATOR
Intervention: Melatonin gel (control)
Number of subjects: 14
Study 25651897 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrestling skills training (experimental group)
Number of subjects: 28
Study 25651897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wrestling skills training)
Number of subjects: 28
Study 25651897 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 28
Study 26621513 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive behaviour therapy (cCBT)
Number of subjects: 36
Study 24354476 — intervention group
Group type: EXPERIMENTAL
Intervention: Multijoint functional training
Number of subjects: 20
Study 24354476 — intervention group
Group type: EXPERIMENTAL
Intervention: Single joint training
Number of subjects: 20
Study 24354476 — intervention group
Group type: COMPARATOR
Intervention: Comparison of multijoint functional and single joint robotic training
Number of subjects: 20
Study 20966360 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT and mindfulness intervention (n = 49)
Number of subjects: 93
Study 20966360 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (n = 44)
Number of subjects: 93
Study 18212332 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking penalization of successful women
Number of subjects: 0
Study 18212332 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback about potential to succeed
Number of subjects: 0
Study 17233364 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 15
Number of subjects: 104
Study 17233364 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 20
Number of subjects: 104
Study 17233364 — intervention group
Group type: COMPARATOR
Intervention: Control group (experience-guided intubation)
Number of subjects: 104
Study 17233364 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 30
Number of subjects: 104
Study 14998221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus an optimized background (OB) regimen
Number of subjects: 0
Study 14998221 — intervention group
Group type: COMPARATOR
Intervention: Optimized Regimen Only (OB)
Number of subjects: 0
Study 14998221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 0
Study 11257563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG): 2 mg/kg BN 52021, administered intravenously 120 mg BN 52021 before reperfusion.
Number of subjects: 24
Study 11257563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (HDG): 10 mg/kg BN 52021, administered intravenously 600 mg BN 52021 before reperfusion.
Number of subjects: 24
Study 11257563 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Placebo administered before reperfusion.
Number of subjects: 24
Study 9374695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 9374695 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 40
Study 9374695 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 40
Study 9374695 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 40
Study 9374695 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 7506166 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 200 mg/day
Number of subjects: 40
Study 7506166 — intervention group
Group type: COMPARATOR
Intervention: ketoprofen 150 mg/day
Number of subjects: 40
Study 2872807 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus diuretic
Number of subjects: 0
Study 2872807 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diuretic
Number of subjects: 0
Study 30951550 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible neurotmesis group (sciatic nerves transected)
Number of subjects: 24
Study 30951550 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham operation)
Number of subjects: 24
Study 27751628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - received orientation to replace processed foods with phosphorus additives with foods without additives
Number of subjects: 134
Study 27751628 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - received only nutritional orientation before the study
Number of subjects: 134
Study 26444980 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quit advice and medicinal nicotine (Condition A)
Number of subjects: 1600
Study 26444980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit or substitute advice and medicinal nicotine (Condition B)
Number of subjects: 1600
Study 26444980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit or substitute advice and medicinal nicotine and e‐cigarettes (Condition C)
Number of subjects: 1600
Study 24086334 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg single dose)
Number of subjects: 97
Study 24086334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 22185601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with heterologous vaccine (HE)
Number of subjects: 110
Study 22185601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with homologous inactivated vaccine (HO)
Number of subjects: 110
Study 22185601 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated (NV)
Number of subjects: 110
Study 19214923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 87
Study 18337638 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) 3 times daily for 4 consecutive weeks
Number of subjects: 22
Study 18337638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15050493 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids
Number of subjects: 10
Study 15050493 — intervention group
Group type: COMPARATOR
Intervention: Fat-free meal (control)
Number of subjects: 10
Study 15050493 — intervention group
Group type: COMPARATOR
Intervention: Meals with saturated fat and monounsaturated fat
Number of subjects: 10
Study 11686822 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMPs) combined with bovine porous bone mineral (BPBM)
Number of subjects: 24
Study 11686822 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 24
Study 9152821 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine dry powder spray at dressing changes
Number of subjects: 130
Study 9152821 — intervention group
Group type: COMPARATOR
Intervention: No povidone iodine spray (control group)
Number of subjects: 130
Study 8253556 — intervention group
Group type: EXPERIMENTAL
Intervention: TANIS stage
Number of subjects: 86
Study 3820066 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking briskly for 10 min
Number of subjects: 18
Study 3820066 — intervention group
Group type: COMPARATOR
Intervention: Candy bar (sugar snack)
Number of subjects: 18
Study 31133096 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention (reducing sodium intake, weight control, exercise, quitting smoking, limiting alcohol consumption)
Number of subjects: 1183
Study 31133096 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention
Number of subjects: 1183
Study 31133096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 1183
Study 28663620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 50
Study 28663620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26088909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control (target BG range of 4.5‐6.0 mmol/L)
Number of subjects: 391
Study 26088909 — intervention group
Group type: COMPARATOR
Intervention: Conventional control (target BG <10 mmol/L)
Number of subjects: 391
Study 26088909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control
Number of subjects: 391
Study 26088909 — intervention group
Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 391
Study 23508563 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 56
Study 23508563 — intervention group
Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 56
Study 21525248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g L-leucine with each main meal (7.5 g/d)
Number of subjects: 60
Study 21525248 — intervention group
Group type: COMPARATOR
Intervention: Placebo with each main meal
Number of subjects: 60
Study 19220847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite silica gel (Group 1, 3 months healing)
Number of subjects: 16
Study 19220847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite silica gel (Group 2, 6 months healing)
Number of subjects: 16
Study 16421464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 1031
Study 16421464 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 1031
Study 12682468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 0.008 mg/kg body weight over 10 mins; if needed, amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Number of subjects: 40
Study 12682468 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Number of subjects: 40
Study 11104872 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg I/ml)
Number of subjects: 0
Study 11104872 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (320 mg I/ml)
Number of subjects: 0
Study 8613058 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (13-15 mg.kg-1.day-1)
Number of subjects: 180
Study 8613058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 1446728 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (3 micrograms/kg/day s.c.) alone
Number of subjects: 21
Study 1446728 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF plus AraC (20 mg/m2/d s.c.)
Number of subjects: 21
Study 3001664 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (5 mg)
Number of subjects: 10
Study 3001664 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (10 mg)
Number of subjects: 10
Study 3001664 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (20 mg)
Number of subjects: 10
Study 3001664 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg)
Number of subjects: 10
Study 3001664 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study 30007274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting (Group 1)
Number of subjects: 23
Study 30007274 — intervention group
Group type: COMPARATOR
Intervention: Fat grafting (Group 2)
Number of subjects: 23
Study 30007274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting (both groups)
Number of subjects: 23
Study 30063588 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 190
Study 27389084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0
Study 27389084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24281134 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033